MX349364B - Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma. - Google Patents

Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma.

Info

Publication number
MX349364B
MX349364B MX2014003183A MX2014003183A MX349364B MX 349364 B MX349364 B MX 349364B MX 2014003183 A MX2014003183 A MX 2014003183A MX 2014003183 A MX2014003183 A MX 2014003183A MX 349364 B MX349364 B MX 349364B
Authority
MX
Mexico
Prior art keywords
alpha
antitrypsin variant
antitrypsin
preparation
present
Prior art date
Application number
MX2014003183A
Other languages
English (en)
Other versions
MX2014003183A (es
Inventor
Sang Mee Lee
Soon Jae Park
Hye-Shin Chung
Ji Sun Kim
Original Assignee
Alteogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alteogen Inc filed Critical Alteogen Inc
Publication of MX2014003183A publication Critical patent/MX2014003183A/es
Publication of MX349364B publication Critical patent/MX349364B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)

Abstract

La presente invención se refiere a una variante de alfa-1 antitripsina preparada al sustituir un aminoácido en un sitio específico ente las posiciones 1 y 25 del N-terminal de la alfa-1 antitripsina para añadir un sitio de glucosilación, en donde el sitio específico es en la posición 9 o 12.
MX2014003183A 2011-09-15 2012-08-13 Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma. MX349364B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20110092819 2011-09-15
KR1020120058998A KR101402702B1 (ko) 2011-09-15 2012-06-01 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도
PCT/KR2012/006441 WO2013039295A1 (ko) 2011-09-15 2012-08-13 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도

Publications (2)

Publication Number Publication Date
MX2014003183A MX2014003183A (es) 2015-01-12
MX349364B true MX349364B (es) 2017-07-26

Family

ID=48179554

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003183A MX349364B (es) 2011-09-15 2012-08-13 Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma.

Country Status (11)

Country Link
US (1) US9051395B2 (es)
EP (1) EP2757110B1 (es)
JP (1) JP6001074B2 (es)
KR (1) KR101402702B1 (es)
CN (1) CN103827141B (es)
AU (1) AU2012309292B2 (es)
BR (1) BR112014005788B1 (es)
CA (1) CA2848919C (es)
MX (1) MX349364B (es)
RU (1) RU2567007C1 (es)
WO (1) WO2013039295A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2857417B1 (en) * 2012-06-05 2018-02-14 CJ Healthcare Corporation Highly glycosylated long-acting human growth hormone protein and production method for same
WO2019125002A1 (ko) 2017-12-20 2019-06-27 (주)알테오젠 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질
KR102167827B1 (ko) * 2017-12-20 2020-10-20 주식회사 알테오젠 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질
EP3802587A4 (en) * 2018-06-07 2022-03-23 Prottech Inc. PHARMACEUTICAL COMPOSITION COMPRISING A FUSION PROTEIN AND USE THEREOF
KR102134571B1 (ko) * 2018-06-15 2020-07-16 주식회사 알테오젠 혈액응고인자 VII/VIIa 융합단백질의 제조 방법
CN113286586A (zh) 2018-06-22 2021-08-20 Ucl商业有限公司 新化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2768557B2 (ja) * 1993-05-18 1998-06-25 コリア・インスティチュート・オブ・サイエンス・アンド・テクノロジー 耐熱性α１−抗トリプシンムテイン
KR0133252B1 (ko) * 1993-05-18 1998-04-14 김은영 내열성의 알파-1-안티트립신 뮤테인
RU2392963C2 (ru) * 2004-08-09 2010-06-27 Элиоз Байофарма, Инк. Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов
WO2008151845A2 (en) 2007-06-15 2008-12-18 Charite - Universitätsmedizin Berlin Methods for producing glycosylated human alpha-1 antitrypsin (a1at) in mammalian host cells
EP2423233B1 (en) * 2009-04-22 2015-03-11 Alteogen, Inc In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
EP2857417B1 (en) * 2012-06-05 2018-02-14 CJ Healthcare Corporation Highly glycosylated long-acting human growth hormone protein and production method for same

Also Published As

Publication number Publication date
JP2014534166A (ja) 2014-12-18
KR20130029713A (ko) 2013-03-25
US9051395B2 (en) 2015-06-09
EP2757110B1 (en) 2017-09-27
CN103827141B (zh) 2016-01-13
US20140371160A1 (en) 2014-12-18
BR112014005788B1 (pt) 2021-01-12
CA2848919C (en) 2016-09-13
MX2014003183A (es) 2015-01-12
WO2013039295A1 (ko) 2013-03-21
EP2757110A1 (en) 2014-07-23
AU2012309292B2 (en) 2015-05-07
RU2014114790A (ru) 2015-10-20
BR112014005788A2 (pt) 2017-03-28
CN103827141A (zh) 2014-05-28
JP6001074B2 (ja) 2016-10-05
AU2012309292A1 (en) 2014-04-24
EP2757110A4 (en) 2015-04-22
KR101402702B1 (ko) 2014-06-05
RU2567007C1 (ru) 2015-10-27
CA2848919A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
MX349364B (es) Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma.
CY1118984T1 (el) Παρασκευη ενεργων, ακρως φωσφορυλιωμενων, ανθρωπινων λυσοσωμικων ενζυμων σουλφατασης και χρησεις αυτων
NZ608502A (en) Polypeptides that bind to human complement component c5
PE20151727A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
CO6382125A2 (es) Inhibidores de proteína quinasa
PH12015500301B1 (en) A novel formulation of diclofenac
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
GB0317466D0 (en) Use
NZ702801A (en) Treatment of sanfilippo syndrome type b
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
MX2013012661A (es) Compuestos de piridazina biciclicos como inhibidores pim.
NZ595903A (en) A novel formulation of metaxalone
TN2011000535A1 (en) A novel formulation of meloxicam
IN2014MN01892A (es)
MX2012012031A (es) Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.
IN2014DN06920A (es)
NZ610620A (en) Inhibitors of apoptosis and uses thereof
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
MX2015007402A (es) Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos.
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral
PH12015502005B1 (en) New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy
EA201391063A1 (ru) Аполипопротеин a-iv в качестве антидиабетического пептида
WO2007138382A3 (en) Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
SMT201300112B (it) Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene

Legal Events

Date Code Title Description
FG Grant or registration